Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …

Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …

Since its approval in 2001 for frontline management of chronic myelogenous leukemia
(CML), imatinib has proven to be very effective in achieving high remission rates and …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Although imatinib revolutionized the management of chronic myeloid leukemia (CML),
recent data indicate a transformation in the treatment approach likely in the near future. For …

Overcoming drug resistance in chronic myeloid leukemia : Current Opinion in Hematology
Overcoming drug resistance in chronic myeloid leukemia : Current Opinion in Hematology Log …

The major mechanism of imatinib resistance for patients with chronic myeloid leukemia
(CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine …

OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …